Activation of protease activated receptor-2 induces delayed cardioprotection in anesthetized mice

Cardiovascular Drugs and Therapy

Volumn 23, Issue 6, 2009, Pages 519-520

  Lim, Shiang Y ^a   Wainwright, Cherry L ^b   Kennedy, Simon ^c   Kane, Kathleen A ^d  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b ROBERT GORDON UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Ischemia; Mice; PAR2; Reperfusion

Indexed keywords

2 CHLORO 6 N CYCLOPENTYLADENOSINE; ADENOSINE RECEPTOR STIMULATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE C; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 2 STIMULATING AGENT; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; OLIGOPEPTIDE; SERYL LEUCYL ISOLEUCYL GLYCYL ARGINYL LEUCINAMIDE; SERYL-LEUCYL-ISOLEUCYL-GLYCYL--ARGINYL-LEUCINAMIDE; TRYPSIN;

DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVATION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISCHEMIC PRECONDITIONING; LETTER; MAST CELL; MAST CELL DEGRANULATION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; ANIMAL; DRUG POTENTIATION; MOUSE;

ANIMALS; MICE; MYOCARDIAL REPERFUSION INJURY; OLIGOPEPTIDES; RECEPTOR, PAR-2; TRYPSIN;

EID: 77649198739     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6073-8     Document Type: Letter

References (10)

1. Bucci M, Roviezzo F, Cirino G. Protease-activated receptor-2 (PAR2) in cardiovascular system. Vascul Pharmacol 2005;43:247-253
2. Jiang R, Zatta AJ, Kin H, et al. PAR2 activation at the time of reperfusion salvages myocardium via an ERK 1/2 pathway in in vivo rat hearts. Am J Physiol Heart Circ Physiol. 2007;in press.
3. Napoli C, Cicala C, Wallace JL, et al. Protease-activated receptor- 2 modulates myocardial ischemia-reperfusion injury in the rat heart. Proc Natl Acad Sci U S A 2000;97:3678-3683
4. Napoli C, de Nigris F, Cicala C, et al. Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning. Am J Physiol Heart Circ Physiol 2002;282:H2004-10.
5. Lim SY, Davidson SM, Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: The essential role of the mitochondrial permeability transition pore. Cardiovasc Res 2007;75:530-535
6. Guo Y, Stein AB, Wu WJ, et al. Late preconditioning induced by NO donors, adenosine A(1) receptor agonists, and delta(1)-opioid receptor agonists is mediated by iNOS. Am J Physiol Heart Circ Physiol 2005;289:H2251-7.
7. Cattaruzza F, Cenac N, Barocelli E, et al. Protective effect of proteinase-activated receptor 2 activation on motility impairment and tissue damage induced by intestinal ischemia/reperfusion in rodents. Am J Pathol 2006;169:177-188
8. Alshurafa HN, Stenton GR, Wallace JL, Hollenberg MD, Befus AD, Vliagoftis H. A protease activated receptor-2 (PAR-2) activating peptide, tc-LIGRLO-NH2, induces protease release from mast cells: role in TNF degradation. BMC Pharmacol 2004;4:12.
9. Stenton GR, Nohara O, Dery RE, et al. Proteinase-activated receptor (PAR)-1 and-2 agonists induce mediator release from mast cells by pathways distinct from PAR-1 and PAR-2. J Pharmacol Exp Ther 2002;302:466-474
10. Parikh V, Singh M. Possible role of cardiac mast cell degranulation and preservation of nitric oxide release in isolated rat heart subjected to ischaemic preconditioning. Mol Cell Biochem 1999;199:1-6.